B A C K G R O U N D
Colorectal cancer is a leading cause of morbidity and mortality, especially in the Western world. Colorectal cancer is the third most commonly diagnosed cancer in males (54.8 per 100,000) and the second in females (34.8 per 100,000) in the United Kingdom (ONS 2005) . In the USA, it is the third most commonly diagnosed cancer in both males (62.7 per 100,000) and females (45.8 per 100,000) (U.S. CDC 2004). Colorectal cancer is the second most commonly diagnosed cancer for males (60.7 per 100,000) and for females (52.1 per 100,000) in Australia (AIHW 2001) .
The human and financial costs of this disease have prompted considerable research efforts to evaluate the ability of screening tests to detect the cancer at an early curable stage. Tests that have been considered for population screening include variants of the faecal occult blood test, flexible sigmoidoscopy and colonoscopy (Winawer 1993) . Reducing mortality from colorectal cancer (CRC) may be achieved by the introduction of population-based screening programmes.
screening for colorectal cancer using the faecal occult blood test (guaiac or immunochemical) reduces colorectal cancer mortality and, secondarily, to evaluate the range of benefits and harms of screening.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials of screening for colorectal cancer using repeated faecal occult blood test (guaiac or immunochemical) were considered for inclusion in the review. For the primary analysis we included trials that used randomisation of individuals or groups.
Types of participants
Adults (18 years or over) participating in controlled colorectal cancer screening trials, either ongoing or completed. Trial participants may be 'volunteers' who agreed to take part in the trial, or individuals or households identified from general practitioner records or population registers.
Types of interventions
Screening using the faecal occult blood test (guaiac or immunochemical) that were undertaken by participants on more than one occasion (e.g. either annually or biennially). The guaiac test slides may or may not be rehydrated. Investigation following a positive faecal occult blood test may be colonoscopy or sigmoidoscopy and double contrast barium enema, with removal of colorectal neoplasms (cancers or adenomas) found at diagnostic investigation.
Types of outcome measures
The primary outcome was reported colorectal cancer mortality in the screening and control groups. Other process measures assessed included:
• the sensitivity of the faecal occult blood test (guaiac or immunochemical) for colorectal cancer,
• the proportion of those allocated to screening who actually attended screening,
• colorectal cancer incidence in the screening and control groups,
• colorectal cancer staging in the screening and control groups,
• all cause mortality in the screening and control groups
We also looked at the physical harms of follow-up colonoscopy or sigmoidoscopy (e.g. reported bowel perforations and haemorrhages due to these procedures). Other important outcomes not explored in this review at this stage included:
• the disruption screening causes to people's lives, • the stress and discomfort from testing and follow-up investigations,
• the anxiety caused by falsely positive screening results, • potential advantages of surgery performed earlier (i.e., for early colorectal cancers).
Search methods for identification of studies
See: Colorectal Cancer search strategy. This review is the second update of the previously published Cochrane Collaboration systematic review (First published 1998 Issue 2).
To identify appropriate studies, we conducted a search using COCHRANE LIBRARY, MEDLINE, EMBASE, CINAHL, PSYCHINFO, AMED, SIGLE, and HMIC electronic databases (searches performed using WebSPIRS -search strategies used available on request). There were no restrictions on language of the articles. Studies identified in the searches published before 1996 were compared with the existing reference list for the previous Cochrane review. Four elements of the search strategy were developed and intersected using the Boolean term 'AND': i. Colorectal cancer subject headings (exploded): colorectal neoplasms. Text words (title and abstract): colorectal*, colon, colonic, bowel*, rectal, rectum, sigmoid, anal, anus combined with cancer*, neoplas*, tumor*, tumour*, carcinoma*, sarcoma*, adenocarcinoma*, adeno?carcinoma*, adenom*, lesion*, CRC ii. Diagnostic methods subject headings (exploded): occult-blood, endoscopy-gastrointestinal, colonoscopes, sigmoidoscope, proctoscope and enema. Text words (title and abstract): faecal, fecal, stool near occult, FOBT, FOB, haemoccult, hemoccult, sensa, coloscreen, seracult, ez-detect, colocare, flexsure, hemmoquant, hemeselect, immudia, monohaem, insure, !nsure, hemodia, instant-view, immocare, magstream, guaiac near1 smear*, endoscop*, proctoscop*; colonoscop*, sigmoidoscop*, rectosigmoidoscop*, proctosigmoidoscop*, COL, SIG, FSIG, barium near1 enema, DCBE iii. Screening subject headings: mass screening, population surveillance. Text words (title and abstract): screen*, test, tests, testing, tested or population* near 1 surveillance, early near 3 detect*, early near 3 prevent* iv. Study search criteria: based on the Cochrane controlled trial filter (Alderson 2005) . The references of all retrieved relevant studies were searched for additional trials. We also wrote to the principal investigators of four of the trials (Funen, Goteborg, Minnesota, Nottingham) 
Data collection and analysis
Two reviewers (PH and PG) contributed to assembling a comprehensive set of articles published between 1989 and 2010 that met the inclusion criteria. The reference list was examined to make certain that the current searches did not miss studies included in the previous Cochrane review. Data from the trials were independently extracted onto standardised critical appraisal forms by two reviewers (PH and EW). Abstracted data included the study citation, study objectives, study design, method of randomisation and blinded assessment of mortality, length of study and follow-up, number of participants (including number of withdrawals), participant characteristics, description of FOB testing regime, characteristics of FOB test (i.e., sensitivity, specificity and positive predictive value), compliance with screening (both overall and for each screening round), number of CRC cases, number of CRC deaths, all cause mortality, number of follow-up diagnostic procedures (e.g. colonoscopies, sigmoidoscopies, etc), compliance with follow-up diagnostic procedures and stage of cancer. The trials identified from the searches were independently assessed for their quality by two reviewers (PH and EW), using the criteria recommended by the Cochrane Collaboration (Alderson 2005) . Using the Cochrane approach to the assessment of allocation concealment, trials were graded as one of four randomisation categories (A = adequate; B = unclear; C = inadequate; D = not used). A method to generate the sequence of randomisation was regarded as appropriate if it allowed each study participant to have the same chance of receiving each intervention and the investigators could not predict which treatment was next (e.g. table of random numbers or computer generated). Disagreements about quality were resolved through discussion with PG. Data analysis was performed using the group subjects were originally randomised to ('intention to screen'), whether or not they were ever screened. To determine the effect of screening on colorectal cancer mortality, we estimated the relative risk and risk difference for each trial, and then overall, using fixed and random effects models and tested for heterogeneity of effects using the chisquared test in Review Manager 5.0.2. Since analysis by intention-to-screen would underestimate any real effect in those attending screening, as a secondary analysis, we adjusted for screening in individual trials using a previously published method (Glasziou 1992) . Essentially, this method divides the intention-to-screen effect (relative risk reduction) by the proportion attending screening.
R E S U L T S Description of studies
See: Characteristics of included studies; Characteristics of excluded studies. The original search (conducted in February 2005) retrieved a total of 4,565 citations. Of these, 1,087 abstracts were duplicates and were excluded, leaving 3,478 abstracts for further consideration. 112 abstracts were reviewed in detail with 21 articles retrieved to determine relevancy for inclusion in the review. Nine publications relating to four randomised controlled trials, and supplementary information from two non-randomised controlled trials, were considered in the updated review (please see table of included studies). An update search of the literature (conducted in February 2006) found a further 317 citations, but no articles were found relevant for inclusion in the review.
Results of the 2010 Update Search
The systematic searches identified 1,271 potentially relevant articles. After adjusting for duplicates, 859 articles remained. Of these, 852 studies were discarded as these papers clearly did not meet the inclusion criteria for the review. Of the 7 remaining studies reviewed in detail, 6 were excluded due to not including a control group. 16 studies were excluded from the review (see table of excluded studies) as ineligible. The cluster randomised trial performed in China (Jiashan: Jiashan 2003; Liu 2000) was excluded from the review as participants were screened only once using a reversed passive hemagglutination (RPHA) FOB test. The other nine studies (Almpoea 2004; California 1993; Calvados 1996; Florence 1997; Guildford 2001; Japan 1995; Milan 1999; New York 1993; Washington 1995) were excluded due to either being non-randomised or non-controlled trials, or used a FOB test on only one occasion in the screening group. Six studies identified in the 2010 update search (Italy 2010; Netherlands 2008; Netherlands 2009; Netherlands 2010; Turin 2010; Tuscany 2008) were excluded from the review due to either being non-randomised or non-controlled trials group.
The four randomised controlled trials included in this review were reported in 12 published articles (Funen: Funen 1996 , Funen 2002 , Funen 2004 Goteborg: Goteborg 1994; Goteborg 1996 , Goteborg 2008 Minnesota: Minnesota 1993 , Minnesota 1999 , Minnesota 2000 Nottingham: Nottingham 1996 , Nottingham 1999 , Nottingham 2002 . One article (Goteborg 2008) was identified from the 2010 update search. The four randomised controlled trials involved 327,043 participants in Denmark, Sweden, USA and the UK. Three trials -the Funen, Goteborg and Nottingham trials -randomly allocated individuals or households identified from general practice records or population registers to invitation with screening with Hemoccult (Nottingham) or Hemoccult-II (Funen, Goteborg) or to control groups. One trial -the Minnesota study -allocated people to either screening (Hemoccult) or control groups only after they had agreed to participate in the trial ('volunteers'). The age of participants ranged from 45 to 75 years for the majority of trials, with the exception of the Goteborg trial where participants were aged 60 to 64 years. The ratio of males and females was similar across the studies (see Table 1 ). The Funen trial (Funen 2004) reported that mean age increased from 59.8 years to 73.0 years during the study and that the male/female ratio decreased from 0.92 to 0.78. The length of follow-up ranged from 8. One randomised trial (Minnesota) evaluated both annual and biennial screening. The number of potential screening rounds varied between the trials. Nine rounds of screening were offered to the screening arm of the Funen trial. Participants in the screening arm of the Goteborg trial were offered a second FOB test one-anda-half to two years after initial screening. In the Minnesota trial, the screening rounds were divided into Phase 1 (between February 1976 and December 1982) and Phase II (between February 1986 and February 1992) . This meant that screening group participants had an interval of between 3 to 5 years between the two phases of the trial. In total, 11 rounds of screening were offered to the annual screening group and 6 rounds of screening were offered to the biennial screening group. Six rounds of screening were offered to participants in the screening arm of the Nottingham trial.
To reduce the rate of a false-positive results, three trials (Funen, Goteborg, Minnesota) encouraged participants to restrict their diet and medications for a specific period before collecting samples for the Hemoccult test. The restrictions varied between studies, but primarily concerned avoiding food containing blood (e.g. red meat, fish, poultry), certain fruits and vegetables, vitamin C and aspirin. Hemoccult slides were not rehydrated in two of the randomised trials (Funen, Nottingham) and both of the controlled trials. Both the Goteborg and Minnesota randomised trials rehydrated the majority of Hemoccult slides. In all of the trials, participants with a positive Hemoccult test were referred for further diagnostic evaluation. Further diagnostic evaluations were expected to be performed by colonoscopy, except for participants in the Goteborg randomised trial who received sigmoidoscopy and double-contrast barium enema.
Risk of bias in included studies
All of the randomised trials (Funen, Goteborg, Minnesota, Nottingham) used an adequate randomisation procedure resulting in comparable study groups. Given that the FOB test was completed by trial participants at home, blinding of participants to the intervention was not possible. Mortality analyses were by "intention to treat" for the Funen, Minnesota and Nottingham randomised trials. This is not specifically stated for the Goteborg trial. One hundred and ninety-seven participants were excluded from the screening group in the Goteborg randomised trials (participants had either died between randomi-sation and screening or could not be located). Blinded, standardised assessment for mortality was performed for all four randomised controlled trials and both controlled trials. The Funen randomised trials included deaths from the complications of treatment for colorectal cancer in the colorectal cancer mortality analyses. This is not specifically stated for the other trials.
Effects of interventions

Meta-analysis of colorectal cancer screening results
Combining the four randomised trials shows that screening results in a statistically significant relative reduction in colorectal cancer mortality of 16% (fixed and random effects models: RR 0.84, CI: 0.78-0.90). This overall result combined the annual and biennial groups in the Minnesota randomised trial as there was little heterogeneity between the effects (Chi-square test for heterogeneity = 1.85, df = 3, P = 0.60, I 2 = 0%).
Sensitivity analysis
Combining the trials that used biennial screening (Minnesota, Nottingham, Goteborg) shows a 15% (fixed and random effects model RR 0.85, CI: 0.78-0.92) relative reduction in colorectal cancer mortality and a slightly larger confidence interval (Chisquare test for heterogeneity = 0.21, df = 3, P = 0.90, I 2 = 0%).
Reduction in mortality adjusted for attendance
The non-compliance rate for the trials ranged from 33% to 46% for the first screen and between 22% and 40% for at least one round of screening. When the relative risk is adjusted for attendance (see below) to screening in the randomised trials, the overall predicted relative mortality reduction is 25% (RR 0.75, CI: 0.66 -0.84) for those screened (analysis not shown -available on request).
Individual trial results
Deaths attributed to colorectal cancer have been published for all of the four trials. The relative risk reductions for colorectal cancer mortality vary from 13% to 33% (see Table 2 ). The Minnesota randomised trial reported a 33% reduction ( All-cause mortality All-cause mortality results are shown in Table 3 . Combining the four trials did not show any significant difference in all-cause mortality between the screening and control groups (fixed effects model: RR 1.00, CI: 0.99-1.02; random effects model: RR 1.00, CI: 0.99-101). There was no important heterogeneity between trials (Chi-squared test for heterogeneity = 1.96, df = 3, p = 0.59, I 2 = 0%). Furthermore, when excluding deaths from colorectal cancer, shows no significant change in non-colorectal cancer mortality between the screening and control groups (fixed and random effects model: RR 1.01, CI: 1.00-1.03). There was no important heterogeneity between trials (Chi-squared test for heterogeneity = 1.42, df = 3, p = 0.70, I 2 = 0%). 
Attendance
The percentage of participants in the screening groups who completed at least one round of screening ranged from 60% to 78% (see Table 4 ). Compliance with screening was higher for the Minnesota trial than for the European trials. Hemoccult screening continued to be offered to all screening participants in most trials, regardless of previous attendance. In the Funen study, only subjects who participated in the first round of screening were invited to subsequent screening rounds, hence, the compliance with Hemoccult testing was very high (91-94%) (Funen 2004) . This may affect the generalisability of the findings of the Funen study. 
Test Accuracy
For two of the trials (Funen, Nottingham), the Haemoccult slides were not rehydrated resulting in a low test positivity rate (0.8% to 3.8%) and a higher positive predictive value for colorectal cancer (5% to 18.7%). In comparison, the test positivity rate for rehydrated slides (Goteborg and Minnesota) was 1.7% to 15.4% and the positive predictive value lower at 0.9% to 6.1% (see Table 5 ). The sensitivity of the Hemoccult test was defined as the proportion of all colorectal cancers that were detected by screening, where "all colorectal cancers" was the sum of screen-detected cancers (true positives) and interval cancers within one or two years of screening (false-negatives). The estimated sensitivity of the Hemoccult test for colorectal cancer varied from 55% to 57% for the nonrehydrated slides (81% for a small sample of participants in the Minnesota trial) and from 82% to 92% for the rehydrated slides. 
Incidence and Stage
As population screening results in earlier cancer diagnosis, we would expect an excess of colorectal cancers detected initially in the screening groups. In the previous Cochrane review, the authors reported that there was an excess of CRC cases for the Funen, Goteborg and Nottingham trials. However, it was uncertain why this did not initially occur for the Minnesota trial (Towler 1998).
A re-examination of this data shows an increased number of CRC cases for the screening groups in the Funen (at 3 years followup CRC cases screen = 147; CRC cases control = 115; Kronborg 1989), Goteborg (at 8.5 years follow-up CRC cases screen = 117; CRC cases control = 44; Goteborg 1994) and Nottingham trials (at 7.8 years follow-up CRC cases screen = 893; CRC cases control = 856; Nottingham 1996). It was suggested that the discrepancy in the number of CRC cases detected in the Minnesota trial (at 13 years follow-up CRC cases annual screen = 323; CRC cases biennial screen = 323; CRC cases control = 356; Minnesota 1993) may have occurred through chance and that this may then also be associated with an underestimation of CRC mortality in the screening groups (Towler 1998). However, it is interesting to note that the Minnesota trial was reporting at 13 years follow-up, in comparison to the much shorter reported length of follow-up for the other trials. Indeed, in a later publication of the Funen trial, the screening and control groups were almost identical in identified CRC cases (at 10 years follow-up CRC cases screen = 481;
CRC cases control = 483; Funen 1996). With further follow-up, the decreasing number of CRC cases occurring over time between the screening and control groups was evident in most of the included trials. In the Funen trial, the number of CRC cases was only slightly higher in the screening groups in comparison to the control groups (see Table 6 ). The Minnesota (CRC cases annual screen = 417; CRC cases biennial screen = 435), Goteborg and Nottingham trials all reported a lower number of CRC cases in comparison to the control groups. This suggests that other factors, rather than chance (see Lang 1994; Church 1997; Ederer 1997) , may have contributed to the reported lower number of CRC cases in the screening groups. There is support for the reduction in the incidence of colorectal cancer following colonoscopic polypectomy (Citarda 2001; New York 1993) . The reduced number of CRC cases for the screening groups most likely reflects the efficacy of colonoscopic polypectomy in preventing adenomas from developing into CRC. Indeed, two of the trials (Funen, Goteborg) reported a very large number of identified adenomas in the screening groups in comparison to the control groups (Funen: screen group = 481 adenomas, control group = 174 adenomas, Kronborg 1989; Goteborg: screen group = 419 adenomas, control group = 51 adenomas, Goteborg 1994). Table 7 ). This favourable shift in colorectal cancer staging occurred across the trials, although the proportion of cancers that were actually screen-detected (e.g. excluding interval cancers, re screening and cancers detected in non-responders to the screening invitation) was fairly low (23% to 46% for Dukes A reported in two of the included trials) (Funen 1996; Nottingham 1996) . 
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Further investigation rates
Rates of further diagnostic evaluation (e.g. colonoscopy or sigmoidoscopy, completion rates for colonoscopy, etc) were reported for all of the included trials. The main investigation was colonoscopy (three of the trials), with only the Goteborg trial using flexible sigmoidoscopy and double-contrast barium enema (DCBE). Around 9 in 10 patients with a positive FOB had further testing. In the Funen trial, 93% of participants with a positive Haemoccult result attended at least one colonoscopy examination. In the Minnesota trial, 83% of the annual screening group and 84% of the biennial group returning a positive FOBT result underwent a colonoscopy or a flexible sigmoidoscopy and double-contrast barium enema.
In the Nottingham trial 87% of participants with a positive result underwent either colonoscopy, double contrast barium enema or both. In the Goteborg trial, 92% of participants with a positive test attended flexible sigmoidoscopy and a double contrast barium enema.
In the two trials that used colonoscopy as the primary means of further investigation (the Goteborg trial primarily used flexible sigmoidoscopy) and reported complications of the procedure, the rate of perforation during colonoscopy is approximately 1 in 1,400 (9/13,720 = 0.0007). Adverse outcomes were reported in detail for 3 of the trials (Goteborg, Minnesota, Nottingham). The Goteborg trial reported adverse outcomes for both flexible sigmoidoscopy and colonoscopy. In this trial, 3 participants (out of 2,108 participants) who received follow-up by flexible sigmoidoscopy had perforations of the sigmoid colon (Goteborg 1996). All three participants recovered without complications. Three complications (out of only 190 procedures) were also reported for participants undergoing colonoscopy in the Goteborg trial (two perforations and one bleeding complication; perforation detected at polypectomy, perforation of sigmoid colon due to colonoscope and bleeding detected 12 days after polypectomy). In the Minnesota trial, of the 12,246 colonoscopies performed at the University of Minnesota hospital there were four perforations of the colon (all requiring surgery) and 11 serious bleeding (3 requiring surgery) complications (Minnesota 1993). The Nottingham randomised trial reported that there were seven complications (out of 1,474 procedures) associated with colonoscopy (five perforations, one major bleed, one snare entrapment) (Nottingham 1999) . Six of these complications required surgery although none of these patients died from the colonoscopy complications. The cumulative risk of being invited for further investigation (either colonoscopy or flexible-sigmoidoscopy) following a positive FOBT was 2.6% (1,977/76,466) for the Nottingham trial, 5.3%
(1,647/30,762 ) for the Funen trial and 6.4% (2,180/34,144) for the Goteborg trial. The total number of positive screening tests is not reported for the Minnesota trial. However, the number of positive screening tests that were followed by an adequate examination (either colonoscopy or flexible sigmoidoscopy and DCBE) were reported as 8,663 for the annual screening group and 5,170 for the biennial screening group (Minnesota 2000) . Based on the reported compliance rate for further investigation (annual = 83%; biennial = 84%), the estimated cumulative risk of being invited for further investigation in the Minnesota trial was 65% for the annual group (8,663/15,570 X 1.17) and 38% for the biennial group (5,170/15,587 X 1.16).
D I S C U S S I O N
The evidence from the randomised controlled trials included in this review, indicates that screening with Haemoccult reduces mortality from colorectal cancer. Based on all randomised participants, the reduction of colorectal cancer mortality from inviting participants to repeat screening is 16% (RR 0.84, CI: 0.78-0.90). Although the trials varied in the selection and age of their study populations, screening intervals, conditions of Haemoccult testing and slide processing, length of follow-up and attendance for screening, the relative reduction in colorectal cancer mortality with screening is consistent across the trials.
The effectiveness of a screening programme depends on the accuracy of the screening test used to detect the condition. The majority of trials reported that the positive predictive value (PPV) of Haemoccult for colorectal cancer was fairly low (see Table 5 ), suggesting that over 80% of all positive tests were false-positives. These false-positive participants would have been encouraged to attend a further diagnostic investigation, which may have resulted in some negative consequences (e.g. stress, anxiety, other psychosocial consequences) and a small chance of significant adverse consequences from the diagnostic test (e.g. risk of bleeding, bowel perforation or even death). Although this must also be tempered by the PPV for adenomas (1 cm or over), which was higher in comparison to the colorectal cancer PPV. Removal of adenomas identified at screening may also reduce the likelihood of the development of colorectal cancer in the future (New York 1993; Citarda 2001), although this has not been definitively demonstrated.
A criticism of the previous Cochrane review was that it did not include an analysis of all-cause mortality. The all-cause mortality from four of the randomised trials (Funen, Goteborg, Minnesota and Nottingham) combined showed no difference between the screening and control groups (RR 1.00, CI: 0.99-1.03). Although the expectation that all-cause mortality would be decreased as a result of a decrease in mortality in the intervention group (Black 2002) this would only be so for diseases that have a significant impact on overall mortality. A major limitation of using all-cause mortality as an endpoint in cancer screening trials is that it is poorly powered as the intervention is targeted to a disease that causes only a small proportion of overall deaths. A complete analysis of the specific reasons for death (e.g. coronary heart disease, stroke, car accidents, etc) contributing to the all-cause mortality would help to determine if people who have survived colorectal cancer die of other causes several (or more years) later.
The estimate of mortality reduction from the updated randomised and controlled Haemoccult trials is consistent. Haemoccult screening is likely to be of benefit in reducing colorectal cancer mortality for particular population groups (e.g. older adults given the increased incidence of colorectal cancer with age). The included trials also indicated that there was a general shift towards identifying colorectal cancer in the earlier stages within the screen-ing groups (e.g. Duke's Stage A) in comparison to the control groups. However, this is to be expected, given that screening studies would identify earlier stage lesions due to lead and length time biases. Other benefits of screening that were not explored in detail include the reduction in colorectal cancer incidence through detection and removal of colorectal adenomas, and potentially, less invasive treatment of identified early-stage colorectal cancers.
Alternative CRC screening modalities to FOBT are currently under investigation or in use. 
A U T H O R S ' C O N C L U S I O N S Implications for practice
Who would be likely to benefit from colorectal cancer screening using Haemoccult? Assuming a constant reduction in relative risk, the mortality benefit of screening is greatest in populations at greater risk of colorectal cancer death whilst the harmful effects of screening are likely to be independent of this risk (Glasziou 1995). Indeed, increasing screening benefit with increasing population risk of colorectal cancer death was observed in the screening trials.
The reduction in the relative risk of colorectal cancer death with screening needs to be interpreted for its benefit in the overall population where there are differing baseline risks for colorectal cancer. For example, the risk of colorectal cancer increases markedly with age and also in people who have a family history of CRC ( 
Implications for research
Several important areas require further research. First, there is relatively little information currently available concerning the information needs and psychosocial consequences of screening for colorectal cancer. Specific research regarding the best method to provide relevant, high-quality information about the benefits, risks and potential consequences of screening is important to allow people to make and informed choice if they are offered screening. Moreover, the specific information needs of people regarding the type of information that is most relevant to their decision and how best to communicate the possible risks associated with colorectal screening also need to be addressed. Second, there is limited research on patient acceptance of colorectal cancer screening or on how best to involve particular sections of the community, who are often under-represented in other screening activities, in potential colorectal cancer screening programmes. Thirdly, the accuracy of other variants of the faecal occult blood test (e.g. RHNA) for colorectal cancer screening also require further investigation, particularly in comparison to existing tests.
Estimated screening benefit for potential screening populations should guide health policy decisions about to whom screening can be offered. For example, in England and Wales in 2004, the cumulative 10 year mortality from colorectal cancer in males for the decades beginning 40, 50 and 60 are respectively 5, 22 and 70 per 10,000 individuals (ONS 2005) . If offering screening reduced this mortality from colorectal cancer by 16%, then the reduction in CRC deaths over the following 10 years for each of these age groups would be 0.8, 3.5 and 11.2 respectively, per 10,000 invited. This somewhat overestimates the benefits of CRC screening, as some of the mortality relates to those diagnosed prior to that decade (ONS 2004) . However, it is also an underestimate for those who regularly attend CRC screening. If we use the mortality reduction of 25% estimated for those who regularly attend screening, the reduction in CRC mortality over 10 years for those aged 40, 50 and 60 would be 1.25, 5.5 and 17.5 per 10,000 respectively. Although the relative risk reduction is held to be constant across the trials, greatest reduction in CRC deaths that could be achieved by CRC screening is dependent on the advancing age of the individual (although, given the lack of an effect for all-cause mortality, an increase in life years may not be observed). Hence targeting and monitoring of population programs also requires attention.
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C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Funen 1996
Methods Random allocation of individuals identified from a population register of Funen county (central randomised procedure adjusted for married couples who were allocated to the same group) Analysis by intention to screen (treat) 6 persons lost to follow-up Blinded standardised assessment of CRC mortality Incidence of CRC similar in the two groups; mortality rates almost identical in the screening and control groups Mortality from CRC less in screening group, but not statistically significant when post-op complications included Risk of death decreased with increasing number of screening rounds (after 9 rounds, RR of death from CRC <0.60 compared with risk in controls); 43% reduction in mortality after 9 screening rounds, 42% after 7 screening rounds, 40% after 5 screening rounds Interval cancer cases better prognosis than controls (survival curves)
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment? Low risk A -Adequate
Goteborg 1994
Methods Random allocation of individuals of Goteborg born between 1918 and 1931 ( 3 cohorts depending on time of birth; 1918-1922, 1923-1927 and 1928-1931 ; the time between inclusion of the 1st and 2nd cohorts was 5 years, the time between the 2nd and 3rd cohorts was 4 years) No indication if intention to screen used for analysis 713 persons in the Screen group died before the second test was sent out and 58 could not be located (Total = 771) 593 persons in the Control group died before the second test was sent out and 29 could not be located (Total = 622) CRC mortality determined by one physician not involved in trial (blinded assessment) 
Risk of bias
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